Lipid management across Europe in the real-world setting: a rapid evidence review
V Barrios, J Soronen, AM Carter… - … Medical Research and …, 2021 - Taylor & Francis
Objective To provide a contemporary overview of recent real-world lipid-lowering therapy
(LLT) practices and outcomes in patients with hypercholesterolemia/dyslipidemia at …
(LLT) practices and outcomes in patients with hypercholesterolemia/dyslipidemia at …
Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial mendelian randomization study
Importance Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase
levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density …
levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density …
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors
Abstract Aims Lipoprotein (a)[Lp (a)] is a lipoprotein species causatively associated with
atherosclerosis. Unlike statins, PCSK9 inhibitors (PCSK9i) reduce Lp (a), but this reduction …
atherosclerosis. Unlike statins, PCSK9 inhibitors (PCSK9i) reduce Lp (a), but this reduction …
Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry
A Cordero, MRF Del Olmo, GAC Quiroga… - Journal of …, 2022 - journals.lww.com
Background: Previous evidence supports that monoclonal antibodies that inhibit the
proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein …
proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein …
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry
A Cordero, MR Fernández Olmo… - European Journal of …, 2022 - Wiley Online Library
Background Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin
type 9 (PCSK9) reduce low‐density lipoprotein cholesterol (LDLc) by 55%, regardless of …
type 9 (PCSK9) reduce low‐density lipoprotein cholesterol (LDLc) by 55%, regardless of …
Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real …
R Scicali, A Di Pino, V Ferrara, AM Rabuazzo… - Acta Diabetologica, 2021 - Springer
Aims Subjects with familial hypercholesterolemia (FH) are characterized by an increased
amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous …
amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous …
[HTML][HTML] Monoclonal anti-PCSK9 antibodies: real-world data
G Guidotti, V Liberati, A Sorrentino, E Lotti… - Journal of Clinical …, 2024 - mdpi.com
Background: Real-world data on the use of lipid-lowering therapy (LLT) in clinical practice
show that about 80% of (very) high-cardiovascular (CV)-risk patients disregard the 2019 …
show that about 80% of (very) high-cardiovascular (CV)-risk patients disregard the 2019 …
Analysis of arterial stiffness and sexual function after adding on PCSK9 inhibitor treatment in male patients with familial hypercholesterolemia: A single lipid center real …
R Scicali, GI Russo, M Di Mauro, F Manuele… - Journal of Clinical …, 2020 - mdpi.com
Familial hypercholesterolemia (FH) subjects have high low-density lipoprotein cholesterol
(LDL-C) and may be at high risk of erectile dysfunction and atherosclerotic cardiovascular …
(LDL-C) and may be at high risk of erectile dysfunction and atherosclerotic cardiovascular …
Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy
M Xu, G Lei, M Chen, K Wang, W Lv, P Zhang, T Hu… - …, 2021 - thelancet.com
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL
cholesterol (LDL-C) levels by facilitating the degradation of the LDL receptor (LDLR) and is …
cholesterol (LDL-C) levels by facilitating the degradation of the LDL receptor (LDLR) and is …
Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
BLK Chng, WMP Heng, YM Soon… - Proceedings of …, 2022 - journals.sagepub.com
Introduction PCSK9 inhibitors demonstrated their effectiveness in reducing low-density
lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains …
lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains …